Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Hepatocellular × tivozanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 11 Colorectal Neoplasms 4 Breast Neoplasms 3 Solid Tumors 2 Sarcoma 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Gastrointestinal Neoplasms 2 Fallopian Tube Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Bile Duct Neoplasms 2 Vulvar Neoplasms 1 Triple Negative Breast Neoplasms 1 Recurrence 1 Neuroendocrine Tumors 1 Neoplasms 1 Liver Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Glioblastoma 1 Gallbladder Neoplasms 1 Disease Progression 1 Disease 1 Clear-cell metastatic renal cell carcinoma 1 Cholangiocarcinoma 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Neuroendocrine 1 Carcinoma, Hepatocellular 1 Advanced Solid Tumors 1 Advanced Adult Hepatocellular Carcinoma 1

Interventions

Sorafenib 202 lenvatinib 128 Bevacizumab 123 Nivolumab 84 pembrolizumab 73 atezolizumab 71 Radiosurgery 71 durvalumab 63 Oxaliplatin 59 sintilimab 55 Fluorouracil 54 Doxorubicin 44 tislelizumab 42 apatinib 42 Leucovorin 40 tremelimumab 37 Radiofrequency Ablation 37 camrelizumab 36 Radiotherapy 36 Magnetic Resonance Spectroscopy 32 Capecitabine 30 regorafenib 29 Folfox protocol 28 Cisplatin 28 Hepatectomy 26 Gemcitabine 26 Cyclophosphamide 26 cabozantinib 25 Ipilimumab 25 toripalimab 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03970616 2023-07-12

DEDUCTIVE

AVEO Pharmaceuticals, Inc.

Phase 1/2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡